Phase I metabolism and disposition study of radiolabelled XP 23829 in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2013
At a glance
- Drugs XP 23829 (Primary)
- Indications Multiple sclerosis; Psoriasis
- Focus Pharmacokinetics
- 09 Sep 2013 Status changed from recruiting to completed.
- 09 Sep 2013 Results were reported in a a XenoPort media release.
- 06 Aug 2013 Results are expected later in the third quarter of 2013, according to a XenoPort media release.